Capecitabine

Capecitabine is a nucleoside metabolic inhibitor with antineoplastic activity indicated for:

Adjuvant Colon Cancer

  • Patients with Dukes' C colon cancer

Metastatic Colorectal Cancer

  • First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred

Metastatic Breast Cancer

  • In combination with docetaxel after failure of prior anthracycline-containing therapy
  • As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen

For indications, dosing and other information, please refer to the prescribing information.

Capecitabine ‐ Amneal

Size:
150 mg, 60 tablets in each bottle
NDC #:
65162-0843-06
Download:
PI
Size:
500 mg, 120 tablets in each bottle
NDC #:
65162-0844-16
Download:
PI

Capecitabine ‐ West-Ward

Size:
150 mg, 60 tablets in each bottle
NDC #:
00054-0271-21
Download:
PI
Size:
500 mg, 120 tablets in each bottle
NDC #:
00054-0272-23
Download:
PI

Capecitabine ‐ Accord

Size:
150 mg, 60 tablets in each bottle
NDC #:
16729-0072-12
Download:
PI
Size:
500 mg, 120 tablets in each bottle
NDC #:
16729-0073-29
Download:
PI